Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis

BACKGROUND: After curative-intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), disease recurrence occurs almost invariably. Evidence guiding treatment of recurrence remains limited and may differ across single-site recurrence patterns. METHODS: Scopus, MEDLINE, and the Cochrane Library were systematically searched for observational studies of adults with recurrent PDAC reporting liver-only, lung-only, or locoregional recurrence and post-recurrence treatments. Hazard ratio (HR) meta-analyses were performed to compare survival outcomes between treatment strategies for each recurrence location with additional descriptive survival summaries. RESULTS: The inclusion criteria were met by 22 studies, with 17 included in the quantitative synthesis. Pattern-specific analyses favored selected local therapies. For liver-only recurrence, local therapy was associated with longer overall survival than chemotherapy alone (HR 0.26, 95% confidence interval [CI] 0.14-0.49), mainly due to surgical resection (HR 0.18; 95% CI 0.11-0.31). Ablation did not reach statistical significance. In lung-only recurrence, surgical resection was associated with longer survival than conventional management (HR 0.35; 95% CI 0.26-0.48). For locoregional recurrence, resection was associated with longer survival (HR 0.52; 95% CI 0.38-0.72). Stereotactic body radiotherapy outcomes from three small series were summarized descriptively. CONCLUSIONS: Pancreatic ductal adenocarcinoma recurrence outcomes differ significantly by recurrence pattern. Across liver-only, lung-only, and locoregional recurrence, selected patients undergoing local therapy had longer survival than those managed conventionally. Although current observational data do not confirm broad efficacy for specific methods, these results support recurrence pattern-specific prospective evaluation to define optimal site-tailored strategies.

Authors

Institutions

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-06-16
DOI
https://doi.org/10.1245/s10434-026-19939-w
Citations
1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
9.73

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis

Giampaolo Perri, Giovanni Marchegiani, Agata Grochowska, Clarissa De Nardi et al.
1 citations
Annals of Surgical Oncology
Pancreatic and Hepatic Oncology Research
9.73
article

Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis

Giampaolo Perri, Giovanni Marchegiani, Agata Grochowska, Clarissa De Nardi, Danhui Heo, Anouk Janine van Bodegraven, Giulia Cemin, Umberto Cillo, Aya Maekawa
article en
1 citations

Abstract

BACKGROUND: After curative-intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), disease recurrence occurs almost invariably. Evidence guiding treatment of recurrence remains limited and may differ across single-site recurrence patterns. METHODS: Scopus, MEDLINE, and the Cochrane Library were systematically searched for observational studies of adults with recurrent PDAC reporting liver-only, lung-only, or locoregional recurrence and post-recurrence treatments. Hazard ratio (HR) meta-analyses were performed to compare survival outcomes between treatment strategies for each recurrence location with additional descriptive survival summaries. RESULTS: The inclusion criteria were met by 22 studies, with 17 included in the quantitative synthesis. Pattern-specific analyses favored selected local therapies. For liver-only recurrence, local therapy was associated with longer overall survival than chemotherapy alone (HR 0.26, 95% confidence interval [CI] 0.14-0.49), mainly due to surgical resection (HR 0.18; 95% CI 0.11-0.31). Ablation did not reach statistical significance. In lung-only recurrence, surgical resection was associated with longer survival than conventional management (HR 0.35; 95% CI 0.26-0.48). For locoregional recurrence, resection was associated with longer survival (HR 0.52; 95% CI 0.38-0.72). Stereotactic body radiotherapy outcomes from three small series were summarized descriptively. CONCLUSIONS: Pancreatic ductal adenocarcinoma recurrence outcomes differ significantly by recurrence pattern. Across liver-only, lung-only, and locoregional recurrence, selected patients undergoing local therapy had longer survival than those managed conventionally. Although current observational data do not confirm broad efficacy for specific methods, these results support recurrence pattern-specific prospective evaluation to define optimal site-tailored strategies.

Annals of Surgical Oncology
University of Padua (IT), University of Szeged (HU), Amsterdam Neuroscience (NL), Medical University of Lodz (PL), Amsterdam University Medical Centers (NL), Institute of Science Tokyo (JP)
Università degli Studi di Padova
Good health and well-being
Openalex Percentile: Top 2%
Pancreatic and Hepatic Oncology Research
9.73
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.